Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Carcinoma, Non-Small-Cell Lung 8Sarcoma 5Neoplasms 5Uterine Cervical Neoplasms 2Small Cell Lung Carcinoma 2Ovarian Neoplasms 2Endometrial Neoplasms 2Carcinoma, Hepatocellular 2Advanced Solid Tumors 2Advanced Cancer 2Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Squamous Non-small Cell Lung Cancer 1Sarcoma, Synovial 1Sarcoma, Alveolar Soft Part 1Pancreatic Neoplasms 1Osteosarcoma 1Neuroendocrine Tumors 1Neoplasm Metastasis 1MSI-H or dMMR Advanced Solid Tumors 1Lung Neoplasms 1Leiomyosarcoma 1Gynecological Cancer 1Gastrointestinal Stromal Tumors 1Gastroenteropancreatic Neuroendocrine Tumor G3 1Fallopian Tube Neoplasms 1Extensive Small Cell Lung Cancer 1Esophageal Squamous Cell Carcinoma 1Digestive System Neoplasms 1Differentiated Thyroid Cancer 1

Interventions

Bevacizumab 6Paclitaxel 5Leucovorin 5Irinotecan 5Fluorouracil 5napabucasin 4Gemcitabine 4Albumin-Bound Paclitaxel 4130-nm albumin-bound paclitaxel 4Ocoxin 3Imatinib Mesylate 3Drug Therapy 3palbociclib 2entinostat 2encorafenib 2Oxaliplatin 2Levoleucovorin 2Folfox protocol 2Everolimus 2Cisplatin 2Cetuximab 25,10-methylenetetrahydrofolic acid 2spartalizumab 1ribociclib 1repotrectinib 1pralsetinib 1pembrolizumab 1olaparib 1linifanib 1irinotecan sucrosofate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Digestive System Neoplasms × anlotinib × Clear all
NCT04207463 2020-06-17

A Study of Anlotinib and AK105 Injection in Subjects With Gastrointestinal Tumors, Urinary System Tumors, Neuroendocrine Tumors

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2 Unknown
150 enrolled
EndocrineGastrointestinalNET

Digestive System Neoplasms, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡